Опубликована: Апрель 30, 2024

Neurologic symptoms associated with Long COVID result from the persistent infection of SARS-CoV-2 in nasal neuroepithelial cells, leading to inflammation central nervous sys-tem (CNS). As today, there is no evidence that vaccines or medications can clear viral olfactory mucosa. Recently published clinical data demonstrate only 5% anosmia patients have fully recovered during past 2 years and 10.4% are still symptomatic 18 months post infection. Our group demonstrated ep-igallocatechin-3-gallate-monopalmitate (EC16m) nanoformulations possess strong antiviral activ-ity against human coronavirus, suggesting this green tea-derived compound nanoparticle for-mulations could be developed as an intranasally delivered new drug targeting infection, well oxidative stress CNS, resto-ration neurologic functions. The objective current study evaluate mucociliary safety EC16m efficacy coronavirus. Meth-ods: size Zeta potential were measured using ZetaView Nanoparticle Tracking Analysis system; was determined MucilAir Human Nasal Epi-thelium Model; contact activity post-infection inhibition OC43 strain assessed by TCID50 assay for cytopathic effect on MRC-5 cells. Results: saline-based EC16 mucoadhesive containing 0.005 0.02% w/v significant difference comparison saline (0.9% NaCl) tissue integrity, cytotoxicity, cilia beat fre-quency. A 5-minute inactivated 99.9% β-coronavirus OC43. replication inhibited >99% after infected MAR-5 cells treated one formulations. Con-clusion: novel rapidly coronavirus measurements comparable saline, a solution widely used applications.

Язык: Английский